<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/base.css" />
<link rel="stylesheet" type="text/css" href="../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/kotobeeInteractive.css" />

    <script type="text/javascript" src="../../../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../../../js/global.js"></script>
<script type="text/javascript" src="../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../js/global.js"></script>

    <title>Phenobarbitone infusions</title>
    

<meta name="m-checksum" content="-1101824111" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="epubypzqs\EPUB\xhtml\sydm84.xhtml" />
<meta name="kotobee-book" content="urn:uuid:a7a011c2-bcc4-851b-034a-24f74f5acdaa" />
</head>
<body>
<p><strong><em>Phenobarbitone in palliative patients should only be used under the direction of a palliative care specialist. Speak to one before initiating phenobarbitone.</em></strong></p>

<p><strong>Indications:</strong></p>

<ul>
	<li>Terminal agitation refractory to other treatments (e.g. midazolam &gt; 60mg/day <em>and </em>either haloperidol &gt; 10mg/day <em>or</em> levomepromazine &gt; 100mg/day) <em>(non-PBS indication)</em></li>
	<li>Status epilepticus or recurrent seizures in an imminently dying patient that has been refractory to benzodiazepine therapy</li>
</ul>

<p><strong>Initial dose:</strong></p>

<ul>
	<li>Give phenobarbitone 200mg IM or subcut</li>
	<li>If agitation continues, give up to 2 further doses IM or subcut, 30 minutes apart</li>
</ul>

<p><strong>Starting a continuous subcutaneous infusion:</strong></p>

<ul>
	<li>Commence an infusion at a dose of between 800mg and 1,200mg over 24 hours via CSCI (diluent is water)</li>
	<li>Use the higher dose for large patients or those who required a larger loading dose</li>
	<li>Use the lower dose for other patients.</li>
</ul>

<p><strong>Additional medications:</strong></p>

<ul>
	<li>Prescribe phenobarbitone 200mg IM or subcut 2-hourly PRN for ongoing agitation</li>
	<li>Continue antipsychotics and midazolam initially â€“ these can be discontinued once agitation is well controlled.</li>
	<li>Do not stop opioids (phenobarbitone is not an analgesic)</li>
</ul>

<table>
	<tbody>
		<tr>
			<td><strong>Precautions</strong></td>
		</tr>
		<tr>
			<td>Stat doses of phenobarbitone subcut have been reported to cause tissue necrosis, therefore IM is preferred</td>
		</tr>
		<tr>
			<td>Phenobarbitone is incompatible with other drugs therefore use a separate syringe pump</td>
		</tr>
		<tr>
			<td>Dilute to the maximum volume possible to reduce site irritation. Manufacturer recommends diluting 10 times.</td>
		</tr>
		<tr>
			<td>Phenobarbitone cannot be mixed with any other medications subcutaneously.</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<p>&#160;</p>

<p>&#160;</p>


</body></html>